Genscript Biotech Gestione
Gestione criteri di controllo 1/4
Genscript Biotech Il CEO è Weihui Shao, nominato in Jul2021, e ha un mandato di 3.33 anni. la retribuzione annua totale è $ 2.48M, composta da 14.3% di stipendio e 85.7% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.034% delle azioni della società, per un valore di HK$ 7.65M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.6 anni e 1.7 anni.
Informazioni chiave
Weihui Shao
Amministratore delegato
US$2.5m
Compenso totale
| Percentuale dello stipendio del CEO | 14.3% |
| Mandato del CEO | 3.3yrs |
| Proprietà del CEO | 0.03% |
| Durata media del management | 3.6yrs |
| Durata media del Consiglio di amministrazione | 1.7yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Market Still Lacking Some Conviction On Genscript Biotech Corporation (HKG:1548)
Nov 19
Is Genscript Biotech (HKG:1548) Using Debt In A Risky Way?
Oct 01What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?
Sep 16After Leaping 44% Genscript Biotech Corporation (HKG:1548) Shares Are Not Flying Under The Radar
Aug 02Slammed 28% Genscript Biotech Corporation (HKG:1548) Screens Well Here But There Might Be A Catch
Jun 05A Look At The Fair Value Of Genscript Biotech Corporation (HKG:1548)
May 10Is Genscript Biotech (HKG:1548) A Risky Investment?
Apr 13Investors Appear Satisfied With Genscript Biotech Corporation's (HKG:1548) Prospects As Shares Rocket 29%
Mar 13Genscript Biotech Corporation (HKG:1548) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Jan 26Is Genscript Biotech (HKG:1548) A Risky Investment?
Nov 21Is Genscript Biotech (HKG:1548) A Risky Investment?
Aug 22Time To Worry? Analysts Just Downgraded Their Genscript Biotech Corporation (HKG:1548) Outlook
Apr 04Analysts Have Been Trimming Their Genscript Biotech Corporation (HKG:1548) Price Target After Its Latest Report
Apr 03Is Genscript Biotech (HKG:1548) A Risky Investment?
Apr 02Genscript Biotech Corporation (HKG:1548) Shares Could Be 25% Below Their Intrinsic Value Estimate
Feb 07What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?
Dec 14Genscript Biotech Corporation (HKG:1548) Shares Could Be 22% Below Their Intrinsic Value Estimate
Nov 09Is Genscript Biotech (HKG:1548) Using Debt Sensibly?
Oct 22Health Check: How Prudently Does Genscript Biotech (HKG:1548) Use Debt?
Apr 03Does Genscript Biotech (HKG:1548) Have A Healthy Balance Sheet?
Oct 03Is It Time To Consider Buying Genscript Biotech Corporation (HKG:1548)?
Sep 07Estimating The Fair Value Of Genscript Biotech Corporation (HKG:1548)
Aug 16Is It Time To Consider Buying Genscript Biotech Corporation (HKG:1548)?
Jun 03Is Genscript Biotech Corporation (HKG:1548) Trading At A 49% Discount?
May 13Is Genscript Biotech (HKG:1548) Using Debt In A Risky Way?
Apr 16Could The Genscript Biotech Corporation (HKG:1548) Ownership Structure Tell Us Something Useful?
Mar 20Are Insiders Selling Genscript Biotech Corporation (HKG:1548) Stock?
Feb 13
Did The Underlying Business Drive Genscript Biotech's (HKG:1548) Lovely 753% Share Price Gain?
Jan 09Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$177m |
| Mar 31 2024 | n/a | n/a | -US$136m |
| Dec 31 2023 | US$2m | US$353k | -US$95m |
Compensazione vs Mercato: La retribuzione totale di Weihui ($USD 2.48M ) è superiore alla media delle aziende di dimensioni simili nel mercato Hong Kong ($USD 481.50K ).
Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Weihui con le performance aziendali.
AMMINISTRATORE DELEGATO
Weihui Shao (44 yo)
3.3yrs
Mandato
US$2,477,000
Compensazione
Ms. Weihui Shao is Chief Operating Officer of Genscript Biotech Corporation from July 08, 2021 and serves as its Rotating Chief Executive Officer since January 01, 2023. She joined the Genscript Biotech Co...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Executive Chairman | 9.3yrs | US$495.00k | 0.013% HK$ 3.0m | |
| CEO & COO | 3.3yrs | US$2.48m | 0.034% HK$ 7.7m | |
| Co-Founder | 22.8yrs | US$659.00k | 0.036% HK$ 8.3m | |
| Co-Founder & Non-Executive Director | no data | Nessun dato | 0.030% HK$ 6.8m | |
| Co-Founder & Executive Director | 1.9yrs | US$531.00k | Nessun dato | |
| Chief Strategy Officer & Executive Director | 4yrs | US$320.00k | 0.054% HK$ 12.2m | |
| Chief Financial Officer | 3.9yrs | Nessun dato | Nessun dato | |
| Chief Marketing Officer for GenScript Life Science Group | no data | Nessun dato | Nessun dato |
3.6yrs
Durata media
56yo
Età media
Gestione esperta: Il team dirigenziale di 1548 è considerato esperto (durata media dell'incarico 3.6 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Executive Chairman | 9.3yrs | US$495.00k | 0.013% HK$ 3.0m | |
| Co-Founder | 9.5yrs | US$659.00k | 0.036% HK$ 8.3m | |
| Co-Founder & Non-Executive Director | 9.5yrs | Nessun dato | 0.030% HK$ 6.8m | |
| Co-Founder & Executive Director | 2.5yrs | US$531.00k | Nessun dato | |
| Chief Strategy Officer & Executive Director | 4yrs | US$320.00k | 0.054% HK$ 12.2m | |
| Member of Advisory Board | less than a year | Nessun dato | Nessun dato | |
| Member of Advisory Board | 5.2yrs | Nessun dato | Nessun dato | |
| Independent Non-Executive Director | less than a year | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | less than a year | Nessun dato | Nessun dato | |
| Independent Non-Executive Director | less than a year | Nessun dato | Nessun dato | |
| Independent Non-Executive Director | less than a year | Nessun dato | Nessun dato | |
| Independent Non-Executive Director | less than a year | Nessun dato | Nessun dato |
1.7yrs
Durata media
61.5yo
Età media
Consiglio di amministrazione esperto: Il consiglio di amministrazione di 1548 non è considerato esperto (durata media del mandato 1.7 anni), il che suggerisce un nuovo consiglio.